NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience.
NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience.
复制标题
DOI：
10.1016/j.ctro.2021.12.012
复制
发表时间：
2022-03
影响因子：
3.1
通讯作者：
Koay EJ
中科院分区：
文献类型：
--
作者：
Bagley AF;Ludmir EB;Maitra A;Minsky BD;Li Smith G;Das P;Koong AC;Holliday EB;Taniguchi CM;Katz MHG;Tamm EP;Wolff RA;Overman MJ;Patel S;Kim MP;Tzeng CD;Ikoma N;Bhutani MS;Koay EJ
NBTXR3是一种由功能化氧化铪纳米粒子组成的放射增敏剂。
本报告描述了首例使用NBTXR3治疗的胰腺癌患者。
首次展示了将NBTXR3局部内镜递送至深部内脏肿瘤。
多学科治疗对于使用NBTXR3治疗胰腺癌患者至关重要。
胰腺导管腺癌（PDAC）仍然是世界上癌症相关死亡的主要原因之一。对于不适合手术的PDAC患者，放射治疗可改善局部疾病控制，但由于周围正常组织的脱靶毒性，安全地给予治疗剂量的放射仍然具有挑战性。NBTXR3是一种由功能化氧化铪结晶纳米粒子组成的新型放射增敏剂，最近在软组织肉瘤、肝细胞癌、头颈部鳞状细胞癌以及伴有肺或肝转移的晚期实体恶性肿瘤中显示出临床活性。在此我们报告首例使用NBTXR3治疗的胰腺癌患者。
一名66岁男性，患有不可切除的局部晚期PDAC，参加了我们的临床试验，接受通过放射治疗激活的NBTXR3。在局部内镜递送NBTXR3之后进行调强放射治疗（IMRT）。随访评估包括体格检查、包括CA19 - 9在内的实验室检查以及胸部、腹部和盆腔的CT检查。
患者通过局部内镜递送接受NBTXR3，未出现任何急性不良事件。放射治疗采用IMRT，每日1次，每次3 Gy，共15次，总剂量为45 Gy。患者在注射NBTXR3后12天开始放疗。每日的轨道CT成像显示在治疗期间NBTXR3保留在肿瘤内。在初次随访评估时，病变在影像学上保持稳定，患者未表现出与治疗相关的毒性。
本报告证明了对于不适合手术的胰腺癌患者，通过放射治疗激活的NBTXR3局部内镜递送的初步可行性。
NBTXR3 is a radioenhancer composed of functionalized hafnium oxide nanoparticles. This report describes the first patient with pancreatic cancer treated with NBTXR3. First demonstration of local endoscopic delivery of NBTXR3 to a deep visceral tumor. Multidisciplinary care critical for treating pancreatic cancer patients with NBTXR3. Pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in the world. For patients with PDAC who are not eligible for surgery, radiation therapy improves local disease control, yet safely delivering therapeutic doses of radiation remains challenging due to off-target toxicities in surrounding normal tissues. NBTXR3, a novel radioenhancer composed of functionalized hafnium oxide crystalline nanoparticles, has recently shown clinical activity in soft tissue sarcoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, and advanced solid malignancies with lung or liver metastases. Here we report the first patient with pancreatic cancer treated with NBTXR3. A 66-year-old male with unresectable locally advanced PDAC was enrolled on our clinical trial to receive NBTXR3 activated by radiation therapy. Local endoscopic delivery of NBTXR3 was followed by intensity modulated radiation therapy (IMRT). Follow-up assessment consisted of physical examination, laboratory studies including CA19-9, and CT of the chest, abdomen, and pelvis. The patient received NBTXR3 by local endoscopic delivery without any acute adverse events. Radiation treatment consisted of 45 Gy in 15 daily fractions using IMRT. The patient began radiation twelve days after NBTXR3 injection. Daily CT-on-rails imaging demonstrated retention of NBTXR3 within the tumor for the duration of treatment. At initial follow-up evaluation, the lesion remained radiographically stable and the patient did not demonstrate treatment-related toxicity. This report demonstrates initial feasibility of local endoscopic delivery of NBTXR3 activated by radiation therapy for patients with pancreatic cancer who are not eligible for surgery.
登录
查看更多内容
影响因子：
6.2
作者：
Amer AM;Zaid M;Chaudhury B;Elganainy D;Lee Y;Wilke CT;Cloyd J;Wang H;Maitra A;Wolff RA;Varadhachary G;Overman MJ;Lee JE;Fleming JB;Tzeng CW;Katz MH;Holliday EB;Krishnan S;Minsky BD;Herman JM;Taniguchi CM;Das P;Crane CH;Le O;Bhosale P;Tamm EP;Koay EJ
通讯作者：
Koay EJ
DOI：
10.1016/j.ijrobp.2015.12.003
发表时间：
2016-03-15
期刊：
International journal of radiation oncology, biology, physics
影响因子：
--
作者：
Krishnan S;Chadha AS;Suh Y;Chen HC;Rao A;Das P;Minsky BD;Mahmood U;Delclos ME;Sawakuchi GO;Beddar S;Katz MH;Fleming JB;Javle MM;Varadhachary GR;Wolff RA;Crane CH
通讯作者：
Crane CH
DOI：
10.1158/1078-0432.ccr-17-3668
发表时间：
2018-12-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Koay EJ;Lee Y;Cristini V;Lowengrub JS;Kang Y;Lucas FAS;Hobbs BP;Ye R;Elganainy D;Almahariq M;Amer AM;Chatterjee D;Yan H;Park PC;Rios Perez MV;Li D;Garg N;Reiss KA;Yu S;Chauhan A;Zaid M;Nikzad N;Wolff RA;Javle M;Varadhachary GR;Shroff RT;Das P;Lee JE;Ferrari M;Maitra A;Taniguchi CM;Kim MP;Crane CH;Katz MH;Wang H;Bhosale P;Tamm EP;Fleming JB
通讯作者：
Fleming JB
影响因子：
3.5
作者：
Schuemann, Jan;Bagley, Alexander F.;Krishnan, Sunil
通讯作者：
Krishnan, Sunil
影响因子：
9.3
作者：
Naidu, Jeevinesh;Bartholomeusz, Dylan;Nguyen, Nam Q.
通讯作者：
Nguyen, Nam Q.